Associated tags: Vertically transmitted infection, GSK, Engineering, Vaccine, Health, Clinical Trials, Pharmaceutical, Biotechnology, Infectious Diseases, Pharmaceutical industry, Infection, Research, Science, Antigen, Shigellosis, Gonorrhea, Disease, Shigella, Doctor of Philosophy
Locations: SWITZERLAND, EUROPE
Health,
Infectious Diseases,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Partnership,
Shigella,
AXA,
Series A round,
Infection,
Doctor of Philosophy,
Novo Holdings A/S,
GSK,
Public,
Vaccine,
Gonorrhea,
Private equity,
Risk,
Novo,
CHF,
Carbohydrate,
Escherichia coli,
Shigellosis,
Global health,
Pharmaceutical industry,
Health care The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea.
Key Points:
- The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea.
- The company expects to announce preliminary results from the Shigella program’s ongoing Phase 2 clinical trial in the second half of 2023.
- "Within the next decade, multiple bacterial infections will become untreatable due to antimicrobial resistance, which is already a significant burden on global health.
- The company’s overall objective is to develop and manufacture highly effective vaccines that can stop the spread of infections caused by emerging antimicrobial resistance.
Biotechnology,
Infectious Diseases,
Health,
Pharmaceutical,
Clinical Trials,
Vaccine,
GSK,
Sirona Dental Systems,
University,
General counsel,
Catholic higher education,
COVID-19,
CureVac,
Organization,
Entrepreneurship,
Infection,
Pharmaceutical industry Dr. Haas joins LimmaTech after 11 years as an executive at CureVac SE, where he most recently served as CEO following his tenures as Chief Corporate Officer and Chief Operating Officer.
Key Points:
- Dr. Haas joins LimmaTech after 11 years as an executive at CureVac SE, where he most recently served as CEO following his tenures as Chief Corporate Officer and Chief Operating Officer.
- Building on the recent in-licensing from GSK of the jointly-developed Phase I/II Shigella program, LimmaTech is poised to achieve several important near-term milestones,” commented Franz-Werner Haas, LL.D., CEO of LimmaTech.
- “His experience, particularly on the frontline of vaccine development during the COVID-19 pandemic, makes him an excellent fit for LimmaTech.
- In 2012, he joined CureVac SE as Chief Corporate Officer and continued his leadership at CureVac as Chief Operating Officer and finally, CEO.
Health,
Infectious Diseases,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Vaccine,
GSK,
Antigen,
Trust,
Bio,
Wellcome Trust,
Infection,
Clinical trial,
Recherche et Industrie Thérapeutiques,
Multimedia,
Shigellosis,
Doctor of Philosophy,
Military personnel,
Death,
Acquisition,
GMMA,
Disease,
Mortality,
Bacteria,
Phase,
Safety,
Pharmaceutical industry,
Shigella “LimmaTech Bio has remained committed to developing our Shigella vaccine candidate and this agreement with GSK has its roots in our successful ongoing partnerships with them.
Key Points:
- “LimmaTech Bio has remained committed to developing our Shigella vaccine candidate and this agreement with GSK has its roots in our successful ongoing partnerships with them.
- LimmaTech Bio signed a research collaboration agreement with GSK to develop novel bioconjugate antigen-based vaccines including a monovalent Shigella vaccine in cooperation with the Wellcome Trust.
- Following positive results from the proof-of-concept human challenge clinical trial with the monovalent Shigella vaccine, LimmaTech initiated the development of a multivalent Shigella vaccine in 2018 with a Wellcome Trust grant received by GSK for the new program.
- LimmaTech will give this candidate vaccine the greatest chance of success, while GSK continues to use its expertise to progress another vaccine in clinical development using a GSK proprietary vaccine platform technology called GMMA.
Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Medical Devices,
Infectious Diseases,
Clinical Trials,
Griffith University,
GSK,
Disease,
Risk,
Griffith,
Woman,
Infection,
Vaccine,
Severe cognitive impairment,
Gonorrhea,
Institute,
HIV,
Vertically transmitted infection,
Acquisition,
Antibody,
Infertility,
Glycomics,
Antigen,
Engineering,
Pharmaceutical industry The company has obtained an exclusive license to a suite of vaccine technologies developed by Professors Michael Jennings and Kate Seib at Griffith Universitys Institute for Glycomics.
Key Points:
- The company has obtained an exclusive license to a suite of vaccine technologies developed by Professors Michael Jennings and Kate Seib at Griffith Universitys Institute for Glycomics.
- LimmaTech will initially use the technologies as well as its in-house expertise to develop the worlds first gonorrhea vaccine.
- Antibiotic resistance and rising rates of gonorrhoea infections worldwide demonstrate the need for a gonococcal vaccine that can protect against potentially life-threatening variants.
- Antibodies against our antigens are functionally active in a variety of relevant assays, demonstrating promising vaccine efficacy, commented Dr. Michael Kowarik, Chief Scientific Officer of LimmaTech.
